COVID-19 'Cicada' Variant Emerges in Multiple U.S. States

A newly identified coronavirus strain designated BA.3.2, informally called the 'Cicada' variant, has been identified across 25 American states and 23 nations as of mid-February. This viral form was initially discovered in South Africa during late 2024 but remained largely undetected until recent reappearance. While currently representing under 1% of analyzed U.S. infections, it constitutes approximately 30% of recent cases in several European countries including Denmark, Germany, and the Netherlands, suggesting potential for increased North American transmission. The variant possesses numerous genetic alterations, with 70-75 mutations in the spike protein compared to earlier dominant strains like JN.1 and LP.8.1, which were considered during development of the 2025-2026 vaccine formulation. Health authorities note these genetic changes may reduce effectiveness of existing immunizations, as laboratory studies indicate the variant can evade antibodies generated by previous infection or vaccination. Medical experts emphasize that current vaccines still provide protection against severe outcomes, though immune response might be delayed. The World Health Organization has classified BA.3.2 as a 'variant under monitoring,' noting no evidence of increased disease severity or mortality. Infectious disease specialists indicate limited clinical data exists beyond laboratory findings, with typical COVID-19 symptoms observed. Vaccination rates have declined, with approximately 17% of American adults receiving the latest immunization as of late February, compared to 22% during the same period last year. Health officials warn that reduced vaccination coverage combined with diminished public health measures increases vulnerability to potential summer surges. At-home testing kits remain effective for detection, as they target stable viral components. Preventive measures include hand hygiene, avoiding crowded indoor spaces when ill, and consulting healthcare providers about concerns.